One of the most promising and studied agents is venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor that can restore the activation of caspase-dependent apoptosis in malignancies, including AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.